Lucidus Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 02-01-2025
- Paid Up Capital ₹ 50.00 K
as on 02-01-2025
- Company Age 4 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.70 M
as on 02-01-2025
- Revenue %
(FY 2022)
- Profit 271.39%
(FY 2022)
- Ebitda -1294.05%
(FY 2022)
- Net Worth 225.34%
(FY 2022)
- Total Assets 704.77%
(FY 2022)
About Lucidus Pharmaceuticals
The Company is engaged in the Home Appliances Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 50.00 K .
The company currently has active open charges totaling ₹0.70 M.
Bijita Pattanaik and Kanhu Sahoo serve as directors at the Company.
- CIN/LLPIN
U51397OR2020PTC035191
- Company No.
035191
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Dec 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Cuttack
Industry
Company Details
- Location
Jagatsinghapur, Odisha, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Lucidus Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bijita Pattanaik  | Director | 17-May-2022 | Current |
| Kanhu Sahoo | Director | 17-May-2022 | Current |
Financial Performance of Lucidus Pharmaceuticals.
Lucidus Pharmaceuticals Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 271.39% increase in profit. The company's net worth Soared by an impressive increase of 225.34%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lucidus Pharmaceuticals?
Unlock access to Lucidus Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹0.70 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 0.07 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 14 Aug 2023 | State Bank Of India | ₹0.70 M | Open |
How Many Employees Work at Lucidus Pharmaceuticals?
Lucidus Pharmaceuticals has a workforce of 0 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lucidus Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lucidus Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
